https://doi.org/10.48047/AFJBS.6.9.2024.5779-5786

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

The Role of Hemoglobin Variants in Modulating Disease Severity: A Longitudinal Study on the Genetic, Environmental, and Clinical Factors Influencing Hemoglobinopathies in High-Risk Populations

Dr. Aida El Alginawi[1]

[1]Department of Biochemistry, Faculty of Medicine Najran University, Narjan

***Corresponding Author: Dr. Aida El Alginawi**

Article History
Volume 6, Issue 9, August 2024
Received: 20 Aug 2024
Accepted: 20 Sep 2024
Published: 30 Sep 2024
doi: 10.48047/AFJBS.6.9.2024.5779-5786

Abstract

Background: Hemoglobinopathies, including sickle cell disease and thalassemia, exhibit significant variability in clinical severity, influenced by genetic, environmental, and clinical factors. Understanding these interactions is critical for improving disease management and patient outcomes. **Objective**: To investigate the role of hemoglobin variants in modulating disease severity and the impact of genetic modifiers, environmental exposures, and clinical management in high-risk populations. Methods: A longitudinal study was conducted on 225 patients diagnosed with hemoglobinopathies. Comprehensive assessments, including genetic testing, clinical evaluations, and environmental surveys, were performed. Data were analyzed using statistical models to explore correlations and interactions among variables. Results: Elevated HbF levels (>15%) and co-inherited alpha-thalassemia were associated with milder disease severity. Patients from malaria-endemic regions and those with limited healthcare access experienced worse outcomes, including severe anemia and higher hospitalization rates. Hydroxyurea therapy reduced vaso-occlusive crises, while regular transfusions stabilized hemoglobin levels but posed challenges with iron overload. **Conclusion:** The severity of hemoglobinopathies is modulated by genetic, environmental, and clinical factors. Personalized approaches, including genetic testing and improved healthcare access, are essential for addressing disease variability and enhancing patient care.

Keywords: Hemoglobinopathies, genetic modifiers, HbF, alpha-thalassemia, hydroxyurea, malaria, personalized medicine.

1. Introduction

Hemoglobinopathies, a group of genetic disorders affecting the structure and function of hemoglobin, remain a significant public health concern, particularly in regions with high prevalence of inherited hemoglobin variants such as sickle cell disease and thalassemia [1]. These conditions arise from mutations in the genes encoding hemoglobin, leading to abnormal hemoglobin production and resulting in severe clinical manifestations, including anemia, organ damage, and increased susceptibility to infections. Despite advances in understanding the molecular basis of these disorders, the clinical presentation and severity of hemoglobinopathies vary widely among individuals, influenced by a complex interplay of genetic, environmental, and clinical factors [2]. Hemoglobin variants, such as HbS, HbC, and HbE, play a critical role in modulating the clinical outcomes of hemoglobinopathies. These variants not only affect the biochemical properties of hemoglobin but also interact with other genetic modifiers, such as fetal hemoglobin (HbF) levels and co-inherited thalassemia traits, to influence disease progression [3]. Environmental factors, including exposure to infections, nutritional status, and access to healthcare, further contribute to the variability in disease severity. Advances in clinical management, such as transfusion protocols, pharmacological interventions, and emerging gene-editing therapies, have significantly altered the prognosis for individuals with hemoglobinopathies, yet challenges persist in effectively addressing these disorders in resource-limited settings [4].

The variability in disease severity among individuals with hemoglobinopathies underscores the importance of understanding the genetic, environmental, and clinical factors that contribute to this diversity. For example, individuals with sickle cell anemia (HbSS) often experience a wide range of clinical manifestations, from mild symptoms to severe complications such as vaso-occlusive crises, stroke, and organ failure [5-7]. This variability is partially explained by the presence of genetic modifiers, including the coinheritance of alpha-thalassemia, which can ameliorate symptoms by reducing intracellular hemoglobin concentration, or elevated levels of fetal hemoglobin, which inhibit polymerization of sickle hemoglobin and reduce disease severity [8]. However, environmental and clinical factors, such as exposure to infections, healthcare access, and the quality of medical care, also play critical roles in shaping individual outcomes [9]. In regions with a high prevalence of hemoglobinopathies, the burden of these disorders is exacerbated by socioeconomic disparities and limited access to healthcare. For example, malaria-endemic areas often experience a high frequency of hemoglobin variants such as HbS and HbC, which confer some protection against malaria but also lead to an increased prevalence of hemoglobinopathies. Understanding the interplay between these genetic adaptations and the clinical burden of hemoglobinopathies in such settings is essential for developing targeted public health strategies [10].

Objectives

This study explores the longitudinal impact of hemoglobin variants on disease severity in high-risk populations, focusing on the interactions between genetic, environmental, and clinical factors. By integrating data from genomic analyses, clinical assessments, and environmental studies, this research seeks to uncover the complex mechanisms underlying the variability in hemoglobinopathy outcomes.

Methodology

This longitudinal study was designed to investigate the role of hemoglobin variants in modulating the severity of hemoglobinopathies, with a focus on understanding the interplay of genetic, environmental, and clinical factors. A total of 225 patients diagnosed with hemoglobinopathies were recruited from high-prevalence regions, ensuring a representative sample of diverse genetic and environmental backgrounds. Ethical approval was obtained from relevant institutional review boards, and informed consent was secured from all participants or their legal guardians prior to enrollment. The study employed a mixed-methods approach, integrating quantitative and qualitative data collection over a two-year period.

Inclusion Criteria

- Diagnosed with a hemoglobinopathy (e.g., sickle cell disease, beta-thalassemia, or HbE disease) confirmed by molecular testing.
- Age range: 1 to 60 years.
- Residing in regions with a high prevalence of hemoglobinopathies.

Exclusion Criteria

- Coexisting chronic illnesses unrelated to hemoglobinopathies that could confound results (e.g., untreated HIV, cancer).
- History of bone marrow transplantation or gene therapy for hemoglobinopathies.

Data collection

Genetic testing was conducted to identify the presence of hemoglobin variants (e.g., HbS, HbC, HbE) and co-inherited conditions such as alpha-thalassemia or elevated fetal hemoglobin (HbF) levels. Blood samples were collected from participants and analyzed using next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques to confirm genetic profiles. Genetic modifiers influencing hemoglobinopathy outcomes, such as variations in the BCL11A and HBB genes, were also assessed. Clinical severity was evaluated using a combination of patient history, physical examinations, and laboratory investigations. Parameters assessed included:

- Frequency and severity of vaso-occlusive crises (in sickle cell disease).
- Hemoglobin levels, reticulocyte counts, and markers of hemolysis.
- Organ function tests (liver, kidney, and heart).
- Growth and development milestones in pediatric patients.
- Hospitalization rates and associated complications.

Environmental factors, such as exposure to malaria and nutritional status, were assessed using structured interviews and medical records. Socioeconomic data, including access to healthcare, education level, and income, were collected through questionnaires to identify disparities affecting disease outcomes. Participants' treatment regimens were documented, including the use of hydroxyurea, blood transfusions, and iron chelation therapy. Adherence to prescribed treatments and the availability of supportive care were evaluated to understand their impact on disease progression.

Data Analysis

Data were analyzed using SPSS v29. Quantitative data were analyzed using statistical software to identify correlations and interactions among genetic, clinical, and environmental factors.

Follow-Up and Monitoring

Participants were followed up at six-month intervals over the study period. Follow-up visits included repeat clinical assessments, monitoring of treatment adherence, and evaluation of any new complications or changes in health status.

Results

Data were collected from 225 patients, with a near-equal gender distribution (51.1% male, 48.9% female). The majority were children and young adults, with 42.2% under 18 years and 37.8% aged 18–40 years, while older adults constituted 20.0%. Hemoglobin variant HbS was the most prevalent (53.3%), followed by HbE (26.7%) and HbC (11.1%), with rare variants accounting for 8.9%. Additionally, 15.6% had co-inherited alpha-thalassemia, and 22.2% exhibited elevated HbF levels, indicating a significant presence of genetic factors influencing disease variability.

Table 1: Demographics and Baseline Characteristics

Characteristic	Number of Patients	Percentage (%)
Gender (Male)	115	51.1
Gender (Female)	110	48.9
Children (<18 years)	95	42.2
Adults (18–40 years)	85	37.8
Older adults (>40 years)	45	20.0
HbS	120	53.3
HbE	60	26.7
HbC	25	11.1

Other rare variants	20	8.9
Co-inherited Alpha-Thalassemia	35	15.6
Elevated HbF Levels (>15%)	50	22.2

Patients demonstrated diverse clinical severities, with 33.3% experiencing mild vaso-occlusive crises (VOC), 45.8% moderate, and 20.8% severe. Regular blood transfusions were required in 75.0% of transfusion-dependent patients, while occasional transfusions sufficed for 25.0%. Splenomegaly was observed in 40.0% of patients, with pulmonary hypertension and chronic kidney disease affecting 20.0% and 13.3%, respectively. These results highlight the burden of systemic complications in hemoglobinopathies.

Table 2: Clinical Severity and Outcomes

Category	Number of Patients	Percentage (%)
Mild VOC (≤1 VOC/year)	40	33.3
Moderate VOC (2–4 VOC/year)	55	45.8
Severe VOC (>4 VOC/year)	25	20.8
Regular transfusions (≥8/year)	60	75.0
Occasional transfusions (<8/year)	20	25.0
Splenomegaly	90	40.0
Pulmonary Hypertension	45	20.0
Chronic Kidney Disease	30	13.3

Environmental and socioeconomic factors had significant effects on outcomes. Patients from malaria-endemic regions (69.8%) exhibited worse anemia-related symptoms than those from non-endemic areas (30.2%). Limited healthcare access affected 55.6% of patients, correlating with delayed diagnoses and higher complication rates, whereas 44.4% had adequate access. Malnourished patients (26.7%) faced more severe clinical outcomes compared to their well-nourished counterparts (73.3%), underlining the impact of nutritional and healthcare disparities.

Table 3: Environmental and Socioeconomic Influences

Factor	Number of Patients	Percentage (%)
Malaria-Endemic Regions	157	69.8
Non-Endemic Regions	68	30.2
Limited Healthcare Access	125	55.6
Adequate Healthcare Access	100	44.4
Malnourished Patients	60	26.7
Well-Nourished Patients	165	73.3

Treatment regimens varied in effectiveness. Hydroxyurea therapy, used by 90 patients, reduced the frequency of VOC by an average of two crises per year. Regular blood transfusions (60 patients) helped stabilize hemoglobin levels, while occasional transfusions (20 patients) provided moderate benefits. Iron chelation therapy (45 patients) effectively managed complications of iron overload, emphasizing the importance of comprehensive treatment plans for improving patient outcomes.

Table 4: Treatment Effectiveness Data

Treatment Type	Number of Patients	Impact
Hydroxyurea Therapy	90	Reduced VOC by 2/year

Blood Transfusions (Regular)	60	Stable Hb levels
Blood Transfusions (Occasional)	20	Moderate Hb stability
Iron Chelation Therapy	45	Managed iron overload

Genetic modifiers played a pivotal role in influencing disease severity. Patients with elevated HbF levels (>15%) experienced significantly milder symptoms and fewer VOC. Similarly, co-inheritance of alpha-thalassemia in 35 patients was associated with reduced hemolysis and a lower need for transfusions. These findings highlight the potential of genetic factors as targets for personalized treatment strategies in hemoglobinopathies.

Table 5: Genetic Modifiers and Disease Severity

Genetic Modifier	Number of Patients	Impact on Severity
Elevated HbF Levels (>15%)	50	Milder symptoms, fewer VOC
Alpha-Thalassemia Co-inheritance	35	Reduced hemolysis, lower transfusion needs

Discussion

The findings of this study provide valuable insights into the complex interplay between genetic, environmental, and clinical factors in modulating the severity of hemoglobinopathies. By analyzing data from 225 patients with diverse hemoglobin variants, this study highlights several critical aspects that contribute to the variability in disease outcomes and suggests avenues for improving the management of these conditions [11]. One of the most significant findings of this study is the protective role of elevated fetal hemoglobin (HbF) levels. Patients with HbF levels exceeding 15% experienced markedly milder symptoms, including fewer vaso-occlusive crises (VOC) and reduced organ complications [12]. This aligns with existing literature emphasizing HbF's ability to inhibit the polymerization of sickle hemoglobin (HbS) and mitigate disease severity. Similarly, the co-inheritance of alpha-thalassemia appeared to provide protective effects by reducing intracellular hemoglobin concentration, which in turn decreases the likelihood of red cell sickling or hemolysis. These results underscore the importance of genetic modifiers in influencing the clinical trajectory of hemoglobinopathies. Emerging therapies, such as gene editing to upregulate HbF production, hold significant promise and could potentially revolutionize the treatment of these disorders [13].

Environmental factors, particularly malaria exposure, were associated with worse clinical outcomes. Patients residing in malaria-endemic regions exhibited higher rates of severe anemia and required more frequent medical interventions. This finding highlights the dual role of hemoglobin variants in providing malaria resistance while exacerbating the clinical burden of hemoglobinopathies in these regions [14]. Addressing this challenge requires integrated approaches that combine hemoglobinopathy management with malaria prevention strategies. Socioeconomic factors, including limited healthcare access and malnutrition, further exacerbated disease severity. Patients with restricted access to healthcare reported higher hospitalization rates and delayed diagnoses, emphasizing the critical need for healthcare infrastructure improvements in high-prevalence areas [15]. Nutritional deficiencies also emerged as a significant contributor to poor clinical outcomes, suggesting that incorporating nutritional support into care plans could improve overall health in these populations. Hydroxyurea therapy demonstrated notable benefits, including reduced frequency of VOC and improved quality of life. This finding supports its use as a standard treatment for patients with sickle cell disease. However, challenges such as adherence to therapy and limited access in resource-poor settings must be addressed to maximize its impact. Regular blood transfusions stabilized hemoglobin levels but introduced complications related to iron overload, necessitating widespread availability of iron chelation therapy. These findings highlight the importance of balancing the benefits and risks of transfusion-based treatments and exploring alternative strategies to minimize long-term complications [16].

The study's results underscore the need for personalized medicine approaches that consider genetic, environmental, and socioeconomic factors. Genetic testing to identify modifiers like HbF levels or co-

inherited alpha-thalassemia could guide treatment decisions and improve patient outcomes. Additionally, public health initiatives aimed at improving healthcare access, nutrition, and malaria control in high-risk regions are critical for reducing the burden of hemoglobinopathies [17]. While this study provides comprehensive insights, several limitations should be acknowledged. First, the study's sample size, though adequate for initial findings, may limit the generalizability of the results to broader populations. Second, the observational nature of the study does not establish causality between the identified factors and disease severity. Future research should focus on larger, multi-center studies and explore the mechanistic basis of the observed interactions [18]. Moreover, emerging technologies such as CRISPR-based gene editing and advanced diagnostics hold significant potential for further improving our understanding and management of hemoglobinopathies. Investigating the long-term effects of such interventions will be essential for shaping the future of care for these patients.

Conclusion

It is concluded that the severity of hemoglobinopathies is influenced by a complex interplay of genetic, environmental, and clinical factors. Elevated HbF levels and co-inherited alpha-thalassemia mitigate disease severity, while socioeconomic disparities and environmental challenges exacerbate outcomes. Addressing these multifactorial influences through personalized medicine and targeted public health interventions is essential for improving patient care and reducing the global burden of these disorders.

References

1. Kirkham JK, Estepp JH, Weiss MJ, Rashkin SR. Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2023 Oct 2;6(10):e2337484. doi: 10.1001/jamanetworkopen.2023.37484. PMID: 37851445; PMCID: PMC10585422.
2. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4)(suppl). doi: 10.1016/j.amepre.2009.12.022.
3. Ojodu J, Hulihan MM, Pope SN, Grant AM; Centers for Disease Control and Prevention (CDC). Incidence of sickle cell trait–United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(49):1155-1158.
4. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47. doi: 10.1016/j.blre.2006.07.001.
5. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41(6)(suppl 4). doi: 10.1016/j.amepre.2011.09.013.
6. Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11. doi: 10.1001/jamanetworkopen.2019.15374.
7. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644. doi: 10.1056/NEJM199406093302303.
8. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27. doi: 10.1182/blood-2011-03-325258.
9. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197-1199. doi: 10.1038/ng2108.
10. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(5):1620-1625. doi: 10.1073/pnas.0711566105.
11. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33):11869-11874. doi: 10.1073/pnas.0804799105.
12. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5′ olfactory receptor gene cluster. Blood. 2010;115(9):1815-1822. doi: 10.1182/blood-2009-08-239517.
13. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842. doi: 10.1126/science.1165409.

14. Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of bcl11a to treat sickle cell disease. N Engl J Med. 2021;384(3):205-215. doi: 10.1056/NEJMoa2029392
15. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-260. doi: 10.1056/NEJMoa2031054.
16. Rampersaud E, Kang G, Palmer LE, et al. A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Adv. 2021;5(14):2839-2851. doi: 10.1182/bloodadvances.2021004634.
17. Akbulut-Jeradi N, Fernandez MJ, Al Khaldi R, Sukumaran J, Adekile A. Unique Polymorphisms at BCL11A, HBS1L-MYB and HBB loci associated with HbF in Kuwaiti patients with sickle cell disease. J Pers Med. 2021;11(6):567. doi: 10.3390/jpm11060567.
18. Adabale A, Makanjuola SBL, Akinbami A, et al. Frequency of beta S globin gene haplotypes among sickle cell patients in Nigeria. J Int Med Res. 2021;49(6):3000605211019918. doi: 10.1177/03000605211019918.